Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries.

Godman B, McCabe H, D Leong T, Mueller D, Martin AP, Hoxha I, Mwita JC, Rwegerera GM, Massele A, Costa JO, do Nascimento RCRM, Lemos LLP, Tachkov K, Milushewa P, Patrick O, Niba LL, Laius O, Sefah I, Abdulsalim S, Soleymani F, Guantai AN, Achieng L, Oluka M, Jakupi A, Logviss K, Hassali MA, Kibuule D, Kalemeera F, Mubita M, Fadare J, Ogunleye OO, Saleem Z, Hussain S, Bochenek T, Mardare I, Alrasheedy AA, Furst J, Tomek D, Markovic-Pekovic V, Rampamba EM, Alfadl A, Amu AA, Matsebula Z, Phuong TNT, Thanh BN, Chichonyi Kalungia A, Zaranyika T, Masuka N, Olaru ID, Wale J, Hill R, Kurdi A, Timoney A, Campbell S, Meyer JC.

Expert Rev Pharmacoecon Outcomes Res. 2020 Apr 1:1-26. doi: 10.1080/14737167.2020.1734456. [Epub ahead of print]

PMID:
32237953
2.

Predictors of loss to follow-up of tuberculosis cases under the DOTS programme in Namibia.

Kibuule D, Aiases P, Ruswa N, Rennie TW, Verbeeck RK, Godman B, Mubita M.

ERJ Open Res. 2020 Mar 16;6(1). pii: 00030-2019. doi: 10.1183/23120541.00030-2019. eCollection 2020 Jan.

3.

Ongoing and planned activities to improve the management of patients with Type 1 diabetes across Africa; implications for the future.

Godman B, Basu D, Pillay Y, Almeida PHRF, Mwita JC, Rwegerera GM, Anand Paramadhas BD, Tiroyakgosi C, Patrick O, Niba LL, Sefah I, Oluka M, Guantai AN, Kibuule D, Kalemeera F, Mubita M, Fadare J, Ogunleye OO, Rampamba EM, Wing J, Mueller D, Alfadl A, Amu AA, Matsebula Z, Kalungia A, Zaranyika T, Masuka N, Wale J, Hill R, Kurdi A, Timoney A, Campbell S, Meyer JC.

Hosp Pract (1995). 2020 Mar 20. doi: 10.1080/21548331.2020.1745509. [Epub ahead of print]

PMID:
32196395
4.

Prevalence of Self-Medication for Acute Respiratory Infections in Young Children in Namibia: Findings and Implications.

Kamati M, Godman B, Kibuule D.

J Res Pharm Pract. 2019 Dec 27;8(4):220-224. doi: 10.4103/jrpp.JRPP_19_121. eCollection 2019 Oct-Dec.

5.

Implications of antibiotic exposure among children in low-income and middle-income countries.

Olaru ID, Kibuule D, Godman B.

Lancet Infect Dis. 2020 Feb;20(2):146-147. doi: 10.1016/S1473-3099(19)30681-4. Epub 2019 Dec 13. No abstract available.

PMID:
31843382
6.

Effective integration of pharmacovigilance systems at public health facilities in resource-limited settings: A qualitative study.

Adenuga BA, Kibuule D, Bamitale KDS, Rennie TW.

Res Social Adm Pharm. 2019 Nov 18. pii: S1551-7411(19)31094-0. doi: 10.1016/j.sapharm.2019.11.010. [Epub ahead of print]

PMID:
31812500
7.

Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future.

Godman B, Haque M, McKimm J, Abu Bakar M, Sneddon J, Wale J, Campbell S, Martin AP, Hoxha I, Abilova V, Anand Paramadhas BD, Mpinda-Joseph P, Matome M, de Lemos LLP, Sefah I, Kurdi A, Opanga S, Jakupi A, Saleem Z, Hassali MA, Kibuule D, Fadare J, Bochenek T, Rothe C, Furst J, Markovic-Pekovic V, Bojanić L, Schellack N, Meyer JC, Matsebula Z, Phuong TNT, Thanh BN, Jan S, Kalungia A, Mtapuri-Zinyowera S, Sartelli M, Hill R.

Curr Med Res Opin. 2020 Feb;36(2):301-327. doi: 10.1080/03007995.2019.1700947. Epub 2019 Dec 30.

PMID:
31794332
8.

Isoniazid acetylation phenotypes in the Sudanese population; findings and implications.

Ali MH, Alrasheedy AA, Kibuule D, Hassali MA, Godman B, Abdelwahab MF, Abbadi RY.

J Clin Tuberc Other Mycobact Dis. 2019 Sep 6;17:100120. doi: 10.1016/j.jctube.2019.100120. eCollection 2019 Dec.

9.

Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries.

Godman B, Grobler C, Van-De-Lisle M, Wale J, Barbosa WB, Massele A, Opondo P, Petrova G, Tachkov K, Sefah I, Abdulsalim S, Alrasheedy AA, Unnikrishnan MK, Garuoliene K, Bamitale K, Kibuule D, Kalemeera F, Fadare J, Khan TA, Hussain S, Bochenek T, Kalungia AC, Mwanza J, Martin AP, Hill R, Barbui C.

Expert Opin Pharmacother. 2019 Dec;20(18):2237-2255. doi: 10.1080/14656566.2019.1684473. Review.

10.

Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications.

Ali MH, Alrasheedy AA, Kibuule D, Godman B, Hassali MA, Ali HMH.

Expert Rev Anti Infect Ther. 2019 Nov;17(11):927-937. doi: 10.1080/14787210.2019.1689818. Epub 2019 Nov 18.

11.

Optimizing data quality of pharmaceutical information systems in public health care in resource limited settings.

Kagoya HR, Kibuule D, Rennie TW, Wuletaw C, Mitonga KH.

Res Social Adm Pharm. 2019 Sep 13. pii: S1551-7411(19)30599-6. doi: 10.1016/j.sapharm.2019.09.057. [Epub ahead of print]

PMID:
31540878
12.

Optimizing spontaneous adverse drug reaction reporting in public healthcare setting in Namibia.

Adenuga BA, Kibuule D, Rennie TW.

Basic Clin Pharmacol Toxicol. 2020 Mar;126(3):247-253. doi: 10.1111/bcpt.13325. Epub 2019 Oct 23.

PMID:
31520574
13.

Clinical Significance of the Plasma Protein Binding of Rifampicin in the Treatment of Tuberculosis Patients.

Verbeeck RK, Singu BS, Kibuule D.

Clin Pharmacokinet. 2019 Dec;58(12):1511-1515. doi: 10.1007/s40262-019-00800-1. No abstract available.

PMID:
31332668
14.

Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan.

Ali MH, Alrasheedy AA, Hassali MA, Kibuule D, Godman B.

Antibiotics (Basel). 2019 Jul 9;8(3). pii: E90. doi: 10.3390/antibiotics8030090.

15.

Essential and forgotten antibiotics: An inventory in low- and middle-income countries.

Tebano G, Li G, Beovic B, Bielicki J, Brink A, Enani MA, Godman B, Hinrichsen SL, Kibuule D, Gabriel LH, Oduyebo O, Sharland M, Singh S, Wertheim HFL, Nathwani D, Pulcini C; European Society of Clinical Microbiology and Infectious Diseases Study Group for Antimicrobial Stewardship.

Int J Antimicrob Agents. 2019 Sep;54(3):273-282. doi: 10.1016/j.ijantimicag.2019.06.017. Epub 2019 Jun 28.

PMID:
31260741
16.

Health workforce planning in Namibia: assessing a pilot workforce survey of pharmacists.

Rennie T, Nangombe V, Mangombe T, Kibuule D, Hunter CJ.

Int J Pharm Pract. 2019 Dec;27(6):565-574. doi: 10.1111/ijpp.12547. Epub 2019 Jun 5.

PMID:
31168887
17.

Effectiveness of community-based DOTS strategy on tuberculosis treatment success rates in Namibia.

Kibuule D, Rennie TW, Ruswa N, Mavhunga F, Thomas A, Amutenya R, Law MR, Günther G, Ette E, Godman B, Verbeeck RK.

Int J Tuberc Lung Dis. 2019 Apr 1;23(4):441-449. doi: 10.5588/ijtld.17.0785.

PMID:
31064623
18.

Developing a grass-roots method for monitoring medicines shortages in southern Africa: Report of a pilot in Namibia.

Rennie T, Kibuule D, Lates J, Gideon H, Nangombe V, Hunter CJ.

Res Social Adm Pharm. 2019 Apr 19. pii: S1551-7411(18)30996-3. doi: 10.1016/j.sapharm.2019.04.046. [Epub ahead of print]

PMID:
31054800
19.

Effectiveness of antibiotic stewardship programmes in primary health care settings in developing countries.

Brinkmann I, Kibuule D.

Res Social Adm Pharm. 2019 Mar 16. pii: S1551-7411(19)30172-X. doi: 10.1016/j.sapharm.2019.03.008. [Epub ahead of print]

PMID:
30904409
20.

Predictors of tuberculosis treatment success under the DOTS program in Namibia.

Kibuule D, Verbeeck RK, Nunurai R, Mavhunga F, Ene E, Godman B, Rennie TW.

Expert Rev Respir Med. 2018 Nov;12(11):979-987. doi: 10.1080/17476348.2018.1520637. Epub 2018 Oct 4.

PMID:
30198358
21.

Validity of World Health Organisation prescribing indicators in Namibia's primary healthcare: findings and implications.

Niaz Q, Godman B, Massele A, Campbell S, Kurdi A, Kagoya HR, Kibuule D.

Int J Qual Health Care. 2019 Jun 1;31(5):338-345. doi: 10.1093/intqhc/mzy172.

PMID:
30169688
22.

Multidisciplinary and multisectoral coalitions as catalysts for action against antimicrobial resistance: Implementation experiences at national and regional levels.

Joshi MP, Chintu C, Mpundu M, Kibuule D, Hazemba O, Andualem T, Embrey M, Phulu B, Gerba H.

Glob Public Health. 2018 Dec;13(12):1781-1795. doi: 10.1080/17441692.2018.1449230. Epub 2018 Mar 20.

PMID:
29557288
23.

Assessing Adherence to Antihypertensive Therapy in Primary Health Care in Namibia: Findings and Implications.

Nashilongo MM, Singu B, Kalemeera F, Mubita M, Naikaku E, Baker A, Ferrario A, Godman B, Achieng L, Kibuule D.

Cardiovasc Drugs Ther. 2017 Dec;31(5-6):565-578. doi: 10.1007/s10557-017-6756-8.

24.

Compliance to guidelines for the prescribing of antibiotics in acute infections at Namibia's national referral hospital: a pilot study and the implications.

Nakwatumbah S, Kibuule D, Godman B, Haakuria V, Kalemeera F, Baker A, Mubita M.

Expert Rev Anti Infect Ther. 2017 Jul;15(7):713-721. doi: 10.1080/14787210.2017.1320220. Epub 2017 May 5.

25.

An analysis of policies for cotrimoxazole, amoxicillin and azithromycin use in Namibia's public sector: Findings and therapeutic implications.

Kibuule D, Mubita M, Naikaku E, Kalemeera F, Godman BB, Sagwa E.

Int J Clin Pract. 2017 Feb;71(2). doi: 10.1111/ijcp.12918. Epub 2017 Jan 16.

26.

Antibiotic use in acute respiratory infections in under-fives in Uganda: findings and implications.

Kibuule D, Kagoya HR, Godman B.

Expert Rev Anti Infect Ther. 2016 Sep;14(9):863-72. doi: 10.1080/14787210.2016.1206468. Epub 2016 Jul 11.

27.

Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.

Verbeeck RK, Günther G, Kibuule D, Hunter C, Rennie TW.

Eur J Clin Pharmacol. 2016 Aug;72(8):905-16. doi: 10.1007/s00228-016-2083-4. Epub 2016 Jun 15. Review.

PMID:
27305904
28.

Outcome of the first Medicines Utilization Research in Africa group meeting to promote sustainable and rational medicine use in Africa.

Massele A, Burger J, Katende-Kyenda NL, Kalemeera F, Kenaope T, Kibuule D, Mbachu O, Mubita M, Oluka M, Olusanya A, Paramadhas BD, van Zyl P, Godman B.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):885-8. doi: 10.1586/14737167.2015.1088386. Epub 2015 Sep 14.

29.

Awareness of, responsiveness to and practice of patients' rights at Uganda's national referral hospital.

Kagoya HR, Kibuule D, Mitonga-Kabwebwe H, Ekirapa-Kiracho E, Ssempebwa JC.

Afr J Prim Health Care Fam Med. 2013 Jun 21;5(1). pii: #491.

30.

An assessment of Makerere University College of Health Sciences: optimizing health research capacity to meet Uganda's priorities.

Nankinga Z, Kutyabami P, Kibuule D, Kalyango J, Groves S, Bollinger RC, Obua C.

BMC Int Health Hum Rights. 2011 Mar 9;11 Suppl 1:S12. doi: 10.1186/1472-698X-11-S1-S12.

31.

Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease.

Boska MD, Hasan KM, Kibuule D, Banerjee R, McIntyre E, Nelson JA, Hahn T, Gendelman HE, Mosley RL.

Neurobiol Dis. 2007 Jun;26(3):590-6. Epub 2007 Mar 6.

Supplemental Content

Loading ...
Support Center